Happy Christmas everyone 🎄🎄🎄

Wishing everyone a very happy new year …

NETTER-2 reports significantly improved PFS in Ki67 10-55% GEP-NETS with first-line #Lutathera vs ⬆️ dose SSA, HR 0.27. Similar benefit in subgroups. #GI24 ⁦@LACNETS⁩ ⁦CarcinoidCancer CCF⁩ ⁦Thor Halfdanarson⁩

Sequencing of Somatostatin-Receptor–Based Therapies in Neuroendocrine Tumor Patients | Journal of Nuclear Medicine jnm.snmjournals.org/content/early/…

ChemoPRRT for higher grade NETs...? Maybe? This small study of well diff NETs randomized 20 pts to PRRT vs. PRRT+CAPTEM. Higher DCR in chemoPRRT (90% vs. 60%) and longer PFS (26 vs. 12 mos). Risk of heme malignancies may not be as relevant in this pop. oce.ovid.com/article/000030…

NETTER-2 Study Results: Beyond the Headlines - neuroendocrinecancer.org.uk/netter-2-study… Thor Halfdanarson Imperial NHS 💙 The Christie NHS Kate 💙 #LetsTalkAboutNETs Novartis bnmsnews Royal Free London

🎙️ Listen back to RTÉ Morning Ireland to hear Tommie Gorman share his personal journey with cancer treatment abroad & the groundbreaking developments happening at #SVUH. Prof. Rachel Crowley discusses the significance of bringing advanced care home #PRRT 👇 rte.ie/radio/radio1/c…

Delighted to present the DIPNECH International case series St Vincent's University Hospital (SVUH) part of at #ENETS24 #NETS #neuroendocrinecancer

Great to see this Irish led collaborative study on DIPNECH presented by Dr. Hussein Almeamar from St Vincent's University Hospital (SVUH) at #ENETS 24.

🎉 Congratulations to our colleague Dr. Hussein Almeamar for clinching 3rd place in the oral category for clinical science at #ENETS24! Your achievement shines a light on our commitment to excellence in medical research. Well done! #SVUHProud #MedicalResearch #ENETS #SVUH #goodnewsfriday

Thank you for sharing your #pheo #para PRRT data! 🔬🙌

2 recent findings supporting aggressive cytoreductive hepatectomy in NET-LM from our group: 1.)Even if the primary can not be identified the overall outcomes are excellent 2.)Concomitant peritoneal disease still have favourable outcomes.More to come! @drsuswarner Mayo Clinic Department of Surgery

Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced G 2–3, well-differentiated, GEP neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study - The Lancet thelancet.com/journals/lance…

Great to have an additional potential option for eligible patients with grade 3 well differentiated GEP NETS, once approved Neuroendocrine Cancer UK #NotJustNECancer UKINETS

Join our new webinar with experts from ENETS @enets.org and NANETS! On 26 June, gain insights into nuclear medicine, PRRT, and multikinase inhibitors. Part 1 covers NETTER-2 and more, while Part 2 dives into trials like CABINET and NATALIE. Don't miss out! enets.org/enets-nanets-w…

A big thank you to all participants and our outstanding panellists from ENETS @enets.org and NANETS for the insightful discussion on the latest research in #PRRT and drug development. Missed it? Watch soon for free in the ENETS webinar archive: enets.org/webinar-archiv…

We discovered a new 🦓 syndrome: bleeding-associated hyperestrogenism in postmenopausal women due to ovarian neuroendocrine tumor metastases. Out now in Euro J Endocrinology: academic.oup.com/ejendo/article…

Free webinar on “Updates on pancreatic neuroendocrine neoplasms”. Details on joining below UKINETS Neuroendocrine Cancer UK #NotJustNECancer

🎯Today is #NETCancerDay! Today the NET community speaks in one global voice to raise awareness: Take a closer look at neuroendocrine cancer! ‼️We appeal to doctors to consider NETs, early detection saves lives. ✅Join us and share the messages: incalliance.org/ncd-2024/

On April 29th, our PRRT Team successfully administered the 100th 177Lu-DOTATATE treatment for patients with Neuro-endocrine Tumours. This innovative therapy helps improve outcomes & quality of life for our patients. Sincere thanks to our dedicated multidisciplinary team! #SVUH